Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 18/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GPR183 | P32249 | 1/20 | 0.33 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5056689 | 0.86 | QPCT (0.40) | QPCTALDH1A1HPGDQPCTL | |
| SCHEMBL5056694 | 0.86 | QPCT (0.40) | QPCTALDH1A1HPGDQPCTL | |
| SCHEMBL5056772 | 0.74 | KDM4E (0.45) | QPCTALDH1A1 | |
| SCHEMBL5056771 | 0.74 | KDM4E (0.45) | QPCTALDH1A1 | |
| SCHEMBL5053494 | 0.73 | QPCT (0.35) | QPCTQPCTL | |
| SCHEMBL14076351 | 0.73 | QPCT (0.35) | QPCTQPCTL | |
| SCHEMBL14076441 | 0.71 | QPCT (0.41) | QPCTQPCTL | |
| SCHEMBL5053524 | 0.68 | QPCT (0.34) | QPCT | |
| SCHEMBL5053522 | 0.68 | QPCT (0.34) | QPCT | |
| SCHEMBL5063881 | 0.68 | QPCT (0.43) | QPCTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | QPCT 9/4885ALDH1A1 1395/4885HPGD 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.